X0306 4 2016-02-02 0 0001382911 Orexigen Therapeutics, Inc. OREX 0001637822 Cannell Thomas R 3344 N. TORREY PINES COURT SUITE 200 LA JOLLA CA 92037 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2015-11-30 4 A 0 5091 2.03 A 5091 D Stock Option (right to buy) 1.78 2016-02-02 4 A 0 390000 A 2026-02-01 Common Stock 390000 390000 D Performance Stock Units 2016-02-02 4 A 0 350000 0.00 A 2021-02-01 Common Stock 350000 350000 D Shares acquired under Issuer's 2013 Employee Stock Purchase Plan. 1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/2/2016, so that all of the shares of the stock subject to the option shall be vested on 2/2/2020, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary on each such date. Not Applicable Grant of performance-vesting stock units ("PSUs") under Issuer's 2007 Equity Incentive Award Plan. The PSUs are subject to vesting in 20% installments over five years from the date of grant but will only be earned during such five year period if pre-determined share price hurdles relating to the 20-trading day average of the closing price of Issuer's common stock are attained. /s/ Thomas P. Lynch, Attorney-in-Fact for Thomas R. Cannell 2016-02-03